+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating whether a structured training program for intensive care unit ICU staff can reduce health problems known as post-intensive care syndrome PICS in adults after they leave the hospital. PICS includes new or worsened physical, thinking, or emotional difficulties following serious illness, which can affect daily life, independence, memory, mood, and overall quality of life. This multicenter study compares patients treated before and after ICU staff training, focusing on whether the training reduces PICS three months after hospital discharge. The study also compares standard training on the ABCDEF care bundle with an expanded A-Z bundle that includes additional care elements like nutrition, sleep, infection prevention, safety, and psychological support. The study involves a cluster-randomized design where entire ICUs are assigned to receive training on either the standard ABCDEF bundle or the expanded A-Z bundle. The training program for ICU staff includes a month-long online course with educational materials, checklists, pocket guides, and visual reminders, plus face-to-face sessions to reinforce learning. After training, ICUs continue usual care while researchers track how often the trained care practices are followed during patients ICU stays, up to 21 days or until discharge or death. Follow-up visits for patients occur at 1, 3, 6, and 12 months after hospital discharge. Participants are adults who stay in the ICU for at least 48 hours and leave the hospital alive. They will undergo tests and questionnaires on physical health, memory, mood, and quality of life during follow-up visits. Data collection includes ICU care details and patient outcomes, monitored using electronic forms with quality checks. The main outcome measured is the number of participants who develop PICS three months after discharge. Secondary outcomes include adherence to care bundles, incidence of delirium, and quality of life assessments at various timepoints. The study runs until 2028 and maintains ethical and data protection standards throughout.

Age: 18Years +All GendersPhase Not Applicable
2 locations
S

Actively Recruiting

Researchers are evaluating a new approach to prevent heart and blood vessel problems in patients with inflammatory rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and systemic lupus erythematosus. These patients have a 50% higher chance of cardiovascular events compared to the general population, and current risk scores often underestimate their true risk. This phase IV clinical trial aims to test if using carotid ultrasound to detect early artery disease can better identify patients at high risk and improve prevention. Participants aged 50 years and older with inflammatory rheumatic diseases and low-to-moderate cardiovascular risk will be randomly assigned to either receive a carotid ultrasound or follow standard care based on current guidelines. Those in the ultrasound group found to have carotid plaques will be classified as very high risk and started on high-intensity statin therapy to lower LDL cholesterol below 55 mgdL. Patients without plaques and those in the control group will receive care according to the European Society of Cardiology 2021 recommendations. The study will last 48 months with ongoing monitoring. Throughout the study, patients will have regular visits to track their health and treatment effects. Those needing lipid-lowering therapy will have monthly visits during treatment adjustment, then every six months until the study ends. All patients will be monitored for major cardiovascular events such as heart attacks, strokes, and hospitalizations over four years. Safety and side effects will also be evaluated, aiming to see if the ultrasound-based strategy better prevents heart problems compared to standard care.

Age: 50Years +All GendersPhase 4
17 locations
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
C

Actively Recruiting

Researchers are comparing two sedation methods for critically ill patients on mechanical ventilation inhaled isoflurane delivered via the Sedaconda ACD-S system versus intravenous propofol. This Phase IV, low-intervention, open-label, randomized controlled trial aims to evaluate which method leads to more ventilator-free days within 28 days post-randomization. The study focuses on patients expected to need deep sedation and mechanical ventilation for over 48 hours in the intensive care unit ICU. Participants will be randomly assigned to one of two groups. One group receives inhaled isoflurane starting at 3 mLh, adjusted to reach a target sedation level without exceeding 14 mLh, guided by end tidal isoflurane concentration. Short periods with higher concentrations may be used. The other group receives intravenous propofol starting at 0.5-1 mgkgh, carefully increased to reach the target sedation without exceeding 4 mgkgh. If sedation targets are not met, a secondary hypnotic may be added in either group. During the study, participants will be monitored for ventilator-free days at 28 days, ICU-free days, time to extubation, sedation effectiveness, use of additional sedatives, and delirium incidence and duration within 28 days. Researchers will also assess mental, cognitive, and quality of life outcomes at 90 days after hospital discharge. Safety, including treatment-related adverse events and mortality up to 60 days, will be tracked. The trial includes 620 patients across multiple centers, with data collected throughout the ICU stay and follow-up periods.

Age: 18Years - 80YearsAll GendersPhase 4
22 locations
C

Actively Recruiting

Researchers are investigating whether certain host factors, including the variety and makeup of intestinal microbiota and genetic markers, are linked to a higher chance of recurrence of Clostridioides difficile infection CDI. The study aims to create a predictive tool that uses epidemiological, clinical, genetic, and microbiologic data to identify patients at greater risk of CDI coming back, within an optimized CDI management setting. This is a multicenter, prospective observational study involving adults diagnosed with CDI according to IDSA criteria. Participants will be part of a stewardship program designed to improve CDI management and enable early detection of CDI recurrence. Blood samples will be collected for genetic testing, and stool samples will be analyzed to study the intestinal microbiome. The study will monitor patients diagnosed with CDI over time without introducing experimental treatments. Throughout the study, researchers will assess the occurrence of CDI recurrence within the first 8 weeks after therapy ends and reinfection between 8 and 24 weeks post-therapy. They will also track hospital readmissions due to CDI during the 24 weeks following treatment completion. Data will be analyzed to identify predictors of recurrence, and the predictive tools accuracy will be evaluated. Participants may expect periodic monitoring as part of the study lasting until December 2029.

Age: 18Years +All Genders
15 locations
O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Beltaven, a subcutaneous allergen-specific immunotherapy, in patients allergic to Apis mellifera, Polistes dominula, or Vespula species. This prospective, open, multi-center observational study includes children and adults receiving care in routine medical practice. The study focuses on patients who have had systemic allergic reactions to hymenoptera stings, aiming to better understand how Beltaven works in real-world settings. Participants receive Beltaven as part of their usual medical care, following a 3-week cluster dosing schedule. The study monitors clinical effectiveness over a 9-month period to assess how the treatment impacts allergic responses. This non-interventional design means that treatments are given as prescribed by doctors, without altering standard care practices. The study collects data during this period to provide insights into Beltavens use in everyday healthcare. During the study, participants will undergo allergy testing including intradermal tests and specific IgE blood tests to confirm their allergy. Researchers will monitor safety and treatment outcomes throughout the 9 months of therapy. The primary measurement is the clinical effectiveness of Beltaven given subcutaneously. Participants health status and any reactions will be observed, with ongoing assessments to ensure safety and support comprehensive data collection over the study timeline.

Age: 14Years +All Genders
13 locations